Managing Directors AGM Presentation
Filed with ASX · · 13 pages · English
Atomo Diagnostics Limited (ASX: AT1) is a medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market Headquartered in Australia with global operations, Atomo develops, manufactures and sells innovative patented products that simplify rapid testing Increasing market traction in the US, Europe and Global Health markets selling approved Ato
In the deck
Story so far
Earlier from Atomo Diagnostics
- Quarterly Activity Report & Appendix 4C - 30 September 2020
- Atomo receives TGA approval for COVID19 antigen test
- Atomo & Access Bio sign deal for rapid antigen test
- DIVOC Labs to sell Atomos COVID-19 test in India
- FY20 Results Presentation
Later from Atomo Diagnostics
- Atomo receives TGA approval for AtomoRapid HIV (1&2) test
- Atomo provides update on its HIV Rapid Test business
- Quarterly Activity Report & Appendix 4C - 31 December 2020
- S&P DJI Announces March 2021 Quarterly Rebalance
- Viatris & Atomo to Support Unitaid HIV Self-Test Expansion
Follow Atomo Diagnostics into a list and get an email when it puts out news.
Follow Atomo Diagnostics